FDA third-party review programme could pay off
This article was originally published in Clinica
Executive Summary
The FDA's third-party review programme has been unsuccessful mainly because companies have been reluctant to pay a fee when the agency reviews their product free of charge. Nonetheless some companies find that paying for a third-party review can be worthwhile in the long run, as they told a conference sponsored last week by the Health Industry Manufacturers Association on getting to market sooner.